Leukemia Clinical Trials in Tennessee

Showing 381-400 of 1,520 trials

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

NCT05275478

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG908, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 192 participants.

Locally Advanced Solid Tumor

Tango Therapeutics, Inc.192 participantsStarted Mar 2022

Los Angeles, California, United States • San Francisco, California, United States • Denver, Colorado, United States +17 more locations

RECRUITINGPhase 1/229 miles

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

NCT05379985

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

Non-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Pancreatic Ductal Adenocarcinoma (PDAC)+1 more

Revolution Medicines, Inc.754 participantsStarted May 2022

Orange, California, United States • Santa Monica, California, United States • Tampa, Florida, United States +13 more locations

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Leukemia Trials in Other Cities

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).

Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Temozolomide With or Without Veliparib in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Functional Lumen Opening With Self-Forming Magnetic Anastomosis

A Trial Evaluating TG4050 in Ovarian Carcinoma.

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Other Conditions in Tennessee